187 related articles for article (PubMed ID: 33723350)
1. PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.
Yang G; Liu S; Maghsoudloo M; Shasaltaneh MD; Kaboli PJ; Zhang C; Deng Y; Heidari H; Entezari M; Fu S; Wen Q; Imani S
Sci Rep; 2021 Mar; 11(1):6056. PubMed ID: 33723350
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise.
Zhao Y; Hasse S; Bourgoin SG
Prog Lipid Res; 2021 Jul; 83():101112. PubMed ID: 34166709
[TBL] [Abstract][Full Text] [Related]
3. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
5. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
6. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
9.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
10. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
12. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
Birkeland E; Busch C; Berge EO; Geisler J; Jönsson G; Lillehaug JR; Knappskog S; Lønning PE
Clin Exp Metastasis; 2013 Oct; 30(7):867-76. PubMed ID: 23673558
[TBL] [Abstract][Full Text] [Related]
13. Testing for
Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
[TBL] [Abstract][Full Text] [Related]
14. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
[TBL] [Abstract][Full Text] [Related]
17. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
18. Phospholipase A1 Member A Activates Fibroblast-like Synoviocytes through the Autotaxin-Lysophosphatidic Acid Receptor Axis.
Zhao Y; Hasse S; Vaillancourt M; Zhao C; Davis L; Boilard E; Fortin P; Di Battista J; Poubelle PE; Bourgoin SG
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884486
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
20. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
